Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
BACKGROUND
An increase in gastric mucosal lesions due to nonsteroidal antiinflammatory drugs (NSAIDs) has been reported along with the aging of society; even orthopedic surgeons can no longer remain unconcerned about this disease. However, no study has accurately examined the incidence of gastric mucosal lesions; therefore, adequate evidence has not been established. In this study, endoscopic examinations were performed to determine the status of gastric mucosal lesions in patients receiving long-term NSAID therapy.


METHODS
In 261 patients receiving NSAIDs other than aspirin for more than 28 days, excluding external application, upper gastrointestinal endoscopy was performed regardless of any subjective symptoms after obtaining the patient's medical history. The severity of the gastric mucosal lesions was evaluated using the modified Lanza score. Patient factors involved in the development of lesions were examined using a logistic regression analysis with criterion variables of gastric mucosal lesions and ulcers and the factors of sex, age, Helicobacter pylori infection, and type of NSAID as candidates for the explanatory variable.


RESULTS
Gastric mucosal lesions were observed in 164 patients (62.8%); 27 (10.3%) had ulcers. The use of diclofenac, subjective symptoms, irregular lifestyle, and increased body mass index (BMI) were four factors associated with the development of gastric mucosal lesions; the odds ratios were 2.99, 1.92, 1.80, and 1.09, respectively. Also, the use of diclofenac, presence of H. pylori, irregular lifestyle, alcohol consumption, and aging were five factors associated with the development of ulcers; the odds ratios were 6.40, 6.07, 2.62, 2.06, and 1.05, respectively.


CONCLUSIONS
Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs. H. pylori infection is a high-risk factor for ulcers in patients receiving long-term NSAIDs therapy. In NSAID-treated patients, subjective symptoms are not grounds for a diagnosis of gastric mucosal lesions, especially ulcers.
Yajima
Hiroshi
H
Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan.
Yamao
Junichi
J
Fukui
Hiroshi
H
Takakura
Yoshinori
Y
D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004008:Diclofenac / Q000009:adverse effects*; D004724:Endoscopy; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D007564:Japan; D008019:Life Style; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010437:Peptic Ulcer / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control; D011446:Prospective Studies; D015363:Quinolones / Q000627:therapeutic use; D012307:Risk Factors
D000897:Anti-Ulcer Agents; D052246:Cyclooxygenase 2 Inhibitors; D015363:Quinolones; D004008:Diclofenac; D015738:Famotidine; C052785:rebamipide; D000409:Alanine